Literature DB >> 16354327

Primary pulmonary lymphoma: current status.

Luciano Wannesson1, Franco Cavalli, Emmanuele Zucca.   

Abstract

Primary pulmonary lymphoma (PPL) is a rare disease with a favorable prognosis compared with lung cancer. Although a number of histologic variables of B- and T-cell lymphoma were reported as PPL, marginal zone lymphoma of the mucosa-associated lymphoid tissue type is by far the most frequent diagnosis. This review summarizes the present knowledge of histopathology, molecular biology, diagnosis, prognosis, and treatment of this heterogeneous entity.

Entities:  

Mesh:

Year:  2005        PMID: 16354327     DOI: 10.3816/CLM.2005.n.049

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN: 1557-9190


  5 in total

1.  Effects of microvascular density on primary pulmonary non-Hodgkin's lymphoma (PPL).

Authors:  Maopeng Yang; Shu Zhao; Xaiosan Zhang; Xiaohong Wang; Minghui Zhang; Yan Wang; Qingyuan Zhang
Journal:  Tumour Biol       Date:  2012-08-09

2.  Primary pulmonary lymphoma: imaging findings in 30 cases.

Authors:  Diletta Cozzi; Catia Dini; Francesco Mungai; Benedetta Puccini; Luigi Rigacci; Vittorio Miele
Journal:  Radiol Med       Date:  2019-10-03       Impact factor: 3.469

3.  Primary pulmonary non-Hodgkin's lymphoma: a retrospective analysis of 29 cases in a Chinese population.

Authors:  Jiajia Huang; Tongyu Lin; Zhi-Ming Li; Ruihua Xu; Huiqiang Huang; Wenqi Jiang
Journal:  Am J Hematol       Date:  2010-07       Impact factor: 10.047

4.  Clinical Features and Surgical Treatment of Primary Pulmonary Lymphoma: A Retrospective Study.

Authors:  Hui Shen; Yaodong Zhou
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

5.  Clinical manifestations of pulmonary mucosa-associated lymphoid tissue lymphoma: single-center experience with 18 patients.

Authors:  Shasha Zhao; Lin Zhang; Zhenyang Gu; Chengying Zhu; Shu Fang; Nan Yang; Feiyan Wang; Lixun Guan; Lan Luo; Chunji Gao
Journal:  Onco Targets Ther       Date:  2018-01-24       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.